PDCD1 and non-small cell lung carcinoma: Our previous research demonstrated that autologous NK cells combined with Programmed Cell Death Protein 1 (PD-1) antibody (Sintilimab) resulted in a 45% ORR and a median PFS of 11.6 months in a second-line treatment setting for NSCLC patients without driver gene mutations (8).